B-SMART - Broadly neutralizing antibodies for SaRNA Mediated Antiviral Response Therapy

The goal of this SBIR Research Topic is to support small businesses in the development of new drug classes with novel mechanisms of action for HIV, Hepatitis B (HBV), and Tuberculosis (Mtb). HBV and Mtb drugs must be compatible with current antiretroviral therapy regimens. The goal of this contract is to improve HBV prevention and treatment by harnessing the power of self-amplifying RNAs (saRNAs) to deliver broadly neutralizing antibodies (bNAbs) and uniquely integrating multiple targeted bNAbs into a single saRNA and using Artificial Intelligence (AI) to optimize the saRNA sequence for longevity and self-amplification. Project Number: 75N93025C00022-0-9999-1 | Fiscal Year: 2025 | NIH Institute/Center: National Institute of Allergy and Infectious Diseases (NIAID) | Principal Investigator: Mark Harlow | Institution: LYNNTECH, INC., COLLEGE STATION, TX | Award Amount: $599,989 | Activity Code: N43 View on NIH RePORTER: https://reporter.nih.gov/project-details/75N93025C00022099991